| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Cellular Biology |
From the Department of Internal Medicine, Cardiovascular Division (A.N.C., R.Y., X.L., L.J., R.B., G.W.S., J.L., A.L.T.), Molecular Physiology and Biological Physics (A.N.C., R.Y., A.L.T.), and Cardiovascular Research Center (A.N.C., R.Y., J.L., A.L.T.), University of Virginia Health System, Charlottesville; and the Transgenic & Molecular Immunogenetics Laboratory (Y.-J.D.), Department of Anesthesiology, Chang, Gung Memorial Hospital, Tauyuan Gueishan, Taiwan ROC.
Correspondence to Amy L. Tucker, Box 801394 MR5, University of Virginia Health System, Charlottesville, VA 22908. E-mail alt8t{at}virginia.edu
Adenosine is a proangiogenic purine nucleoside released from ischemic and hypoxic tissues. Of the 4 adenosine receptor (AR) subtypes (A1, A2A, A2B, and A3), the A2 and A3 have been previously linked to the modulation of angiogenesis. We used the chicken chorioallantoic membrane (CAM) model to determine whether A1 AR activation affects angiogenesis. We cloned and pharmacologically characterized chicken AR subtypes to evaluate the selectivity of various agonists and antagonists. Application of the A1 AR-selective agonist N6-cyclopentyladenosine (CPA; 100 nmol/L) to the CAM resulted in a 40% increase in blood vessel number (P<0.01), which was blocked by the A1 AR-selective antagonist C8-(N-methylisopropyl)-amino-N6-(5'-endohydroxy)-endonorbornan-2-yl-9-methyladenine (WRC-0571; 1 µmol/L). Selective A2A AR agonists did not stimulate angiogenesis in the CAM. In an ex vivo rat aortic ring model of angiogenesis that includes cocultured endothelial cells, fibroblasts, and smooth muscle cells, 50 nmol/L CPA did not directly stimulate capillary formation; however, medium from human mononuclear cells pretreated with CPA, but not vehicle, increased capillary formation by 48% (P<0.05). This effect was blocked by WRC-0571 (1.5 µmol/L) or anti-VEGF antibody (1 µg/mL). CPA (5 nmol/L) stimulated a 1.7-fold increase in VEGF release from the mononuclear cells. This is the first study to show that A1 AR activation induces angiogenesis. Stimulation of A2 ARs on endothelial cells results in proliferation and tube formation, and A2 and A3 ARs on inflammatory cells modulate release of angiogenic factors. We conclude that adenosine promotes a coordinated angiogenic response through its interactions with multiple receptors on multiple cell types.
Key Words: angiogenesis receptor pharmacology growth factors/cytokines
Related Article:
Circ. Res. 2007 101: 1075-1077.
This article has been cited by other articles:
![]() |
S. Nakav, O. Naamani, C. Chaimovitz, G. Shaked, D. Czeiger, M. Zlotnik, and A. Douvdevani Regulation of adenosine system at the onset of peritonitis Nephrol. Dial. Transplant., October 26, 2009; (2009) gfp542v1. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Y. Cheranov, M. Karpurapu, D. Wang, B. Zhang, R. C. Venema, and G. N. Rao An essential role for SRC-activated STAT-3 in 14,15-EET-induced VEGF expression and angiogenesis Blood, June 15, 2008; 111(12): 5581 - 5591. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Shen and P. E. DiCorleto Adenosine Prompts the Heart to Recruit Endothelial Progenitors Circ. Res., February 15, 2008; 102(3): 280 - 282. [Full Text] [PDF] |
||||
![]() |
J. A. Auchampach Adenosine Receptors and Angiogenesis Circ. Res., November 26, 2007; 101(11): 1075 - 1077. [Full Text] [PDF] |
||||
|
Circulation Research Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2007 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |